Consult
Log In
Menu
Consult
Log in

by Josh Forsythe, on April 10, 2018

Cardiovascular disease causes more deaths worldwide than any other disease. In 2015 alone, nearly 18 million people died from cardiovascular disease. And according to the World Health Organization, most cardiovascular disease can be prevented or successfully treated by eliminating risk factors such as smoking and tobacco use, obesity, and physical inactivity. [1]

Read Story
Topics:News

by Josh Forsythe, on April 6, 2018

PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that TriCore Reference Laboratories will utilize the company’s Clinical Genomics WorkSpace™ (CGW) platform, the industry’s leading integrated workspace for genomic analytics, classification, interpretation and reporting. TriCore will join more than 50 other customers who benefit from shared interpretations in the PierianDx KnowledgeSpace, a knowledgebase comprised of millions of biomedical findings that are continually updated.

Read Story
Topics:News

by Josh Forsythe, on April 6, 2018

Flashback: the Human Genome Project was launched in 1990 by Nobel Laureate, Dr. James Watson, at the NIH (National Institutes of Health). All told, sequencing the first human genome took 13 years and cost between $500 million and  $1 billion. Although exciting, the initiative attracted its share of critics who described the initiative as “nearly impossible,” and “un-thought-out science,” because it was behind schedule and over budget from the start, not to mention that it would generate a vast amount of “uninterpretable and useless data.” [1]

Read Story
Topics:News

by Josh Forsythe, on April 5, 2018

In case you missed it, PierianDx customer, Inova, is launching a joint study with the National Institutes of Health (NIH) to “re-engineer” genomics. The study, called the Genomic Ascertainment Cohort (TGAC), launched in early March, will collect the genomes of 10,00 people, and then use analytics to predict phenotypic outcomes using genes and gene variants identified in the genomes. [1]

Read Story
Topics:News

by Josh Forsythe, on April 3, 2018

The drive to deliver precision medicine has galvanized many hospitals to in-source next generation sequencing (NGS) testing. Yet for hospital labs just getting started, the process can be overwhelming. They must build the business case for bringing test in-house and devise effective reimbursement strategies. At the same time, they must fully understand and learn to navigate Clinical Laboratory Improvement Amendment (CLIA) College of American Pathologists (CAP) guidelines and build workflows and an ecosystem that can support their sample volumes now and into the future.

Read Story
Topics:News

by Josh Forsythe, on March 28, 2018

Life gets better when we enter our "golden years" and retire, doesn’t it?  Not necessarily. Because we are living longer, we face the possibility of living with an age-related chronic disease. Cancer, diabetes, and heart disease top the list of conditions we have the potential to acquire as we age.

Read Story
Topics:News

by Josh Forsythe, on March 26, 2018

The Moffitt Morsani Molecular Laboratory, located within the Moffitt Cancer Center, announced today that it has launched a new clinical NGS assay, Solid Tumor Actionable Result, or STAR. STAR is based off of the Illumina TruSight Tumor 170 panel that interrogates 170 genes thought to be drivers in the development of solid tumors.

Read Story
Topics:News

by Josh Forsythe, on March 26, 2018

PierianDx will be highlighting germline features of its genomics technology platform the American College of Medical Genetics and Genomics (ACMG) annual meeting April 10-14 in Charlotte, North Carolina.

Read Story
Topics:News

by Josh Forsythe, on March 23, 2018

When CMS initiated a national coverage analysis for NGS-based testing for advanced cancer on November 30, 2017, it stirred up a lot of debate among the leaders in precision medicine, and more specifically, PierianDx’s partner network of academic medical centers, cancer centers and health systems. For our customers, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the proposed policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.

Read Story
Topics:CMS NCD on Genomic TestingNews

by Josh Forsythe, on March 19, 2018

We are excited to attend the upcoming Precision Oncology Experimental Therapeutics (POET) Congress in Calgary, Alberta the first week in April. We will have an opportunity to collaborate with precision medicine luminaries from Canada and around the world on how best to transition novel biomarker research into routine cancer management.

Read Story
Topics:News

by Josh Forsythe, on March 16, 2018

On April 5 and 6 oncology leaders will convene in Calgary, Alberta to participate in the 2nd International Precision Oncology and Experimental Therapeutics (POET) Congress. The annual meeting supports the education arm of the POET Congress research program that works to incorporate novel biomarker-driven phase I clinical trials research into practical routine cancer management.  The goal of the congress is to accelerate education and knowledge dissemination of the most current novel interrogative-based approaches that drive precision oncology forward.

Read Story
Topics:News

by Josh Forsythe, on March 16, 2018

Genetic diseases are the leading cause of death for infants in North America, affecting an estimated 4 percent of newborns. In MIT Technology Review, Rady Children’s Hospital in San Diego showcases the “new wave of precision medicine” that uses genetics to determine life saving drug options for newborns.

Read Story
Topics:News